



[Home](#) » [Submission Tool and Repository Measure Database](#)

# Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

**CBE ID:** 0081 **Project:** [Cardiovascular](#) **Endorsed:** Thu, 10/24/2019 - 08:13

**New or Maintenance:** [Maintenance](#) **Endorsement and Maintenance (E&M) Cycle:** [Spring 2019](#)

**Is Under Review:** No

## Measure Description:

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

## Measure Specifications

### Measure Type:

[Process](#)

### Electronic Clinical Quality Measure (eCQM):

[No](#)

### Level Of Analysis:

- [Clinician: Group/Practice](#)
- [Clinician: Individual](#)

### Care Setting:

- [Home Care](#)
- [Inpatient/Hospital](#)
- [Other Care Setting.\(Please specify\).](#)
- [Outpatient Services](#)

### Numerator:

Patients who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

**Denominator:**

All patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40%

**Exclusions:**

Denominator Exceptions:

Documentation of medical reason(s) for not prescribing ACE inhibitor or ARB or ARNI therapy (e.g., hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons).

Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB or ARNI therapy (e.g., patient declined, other patient reasons).

Documentation of system reason(s) for not prescribing ACE inhibitor or ARB or ARNI therapy (e.g., other system reasons).

**Testing Data Sources:** • [Registry data](#)

## Characteristics

---

**Measure Structure:**

[Single Measure](#)

**Clinical Condition Topic Area:**

- [Cardiovascular](#)
- [Congestive Heart Failure](#)

**Target Population:**

- [Elderly](#)

**Measure Selection Attributes:**

- [Highest Opportunity for Improvement](#)
- [Lowest Data Collection Burden](#)

**National Quality Strategy Priorities:**

- Prevention and Treatment

## Risk Adjustment

**Risk Adjustment:**

- [No risk adjustment or risk stratification](#)

## Use & Usability

**Current or planned use(s):** • [Payment Program](#)

- [Public Reporting](#)
- [Quality Improvement \(Internal to the specific organization\)](#)

**Current Use(s):** • [Payment Program](#)

- [Public Reporting](#)
- [Quality Improvement \(Internal to the specific organization\)](#)

## Measure Record

**Most Recent Endorsement Activity:**

Endorsed Cardiovascular Spring Cycle 2019

**Initial Endorsement:**

2009-08

**Next Planned Maintenance Review:**

Cardiovascular Spring 2025

**Endorsement Status:**

[Endorsed](#)

**Last Updated:**

2019-10

## Point of Contact

**Steward:**

[American College of Cardiology](#)

**Steward Organization Email:**

lslatter@acc.org

**Steward Organization Copyright:**

Copyright 2019 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

**Public Comments****Staff Preliminary Assessment****Committee Independent Review**

[Return to top](#)

## Contact PQM

PQM powered by Battelle

PQMSupport@battelle.org

800-444-5234

HEALTH CARE QUALITY SOLUTIONS

